Abstract
Interleukin 18 (IL-18) is an IL-1 super family cytokine that is involved in infection, inflammation and autoimmune diseases. Mounting evidence suggests that IL-18 exert a dual role in inflammation and homeostasis. IL-18 can act as a promoter of T cell immunities, such as type 1 and 17 helper T cell responses, and thus enhances T cell-mediated inflammation, whereas IL-18 increases the barrier function and regeneration of epithelial cells and protects the host from inflammatory stimuli. Although the functional role of IL-18 in regulation of inflammation remains controversial, accumulating evidence indicates the contribution of IL-18 to the pathogenesis of inflammatory bowel diseases (IBD). For example, levels of serum and/or mucosal IL-18 and IL-18 binding protein are elevated in the patients with IBD. Furthermore, polymorphisms in IL-18 and IL-18-related molecules, such as the IL-18 receptor and/or an IL-18 activator NLRP3, genes are found in the patients with IBD. Thus, these preclinical data imply that IL-18 can be a novel therapeutic target for the treatment of IBD. In this review, we focus on IL-18 biology and physiological roles in animal models and human IBD, to provide an outline for development of IL-18 blockade strategies.
Keywords: IL-18, IL-18BP, inflammatory bowel disease, Crohn’s disease, ulcerative colitis.
Current Drug Targets
Title:Clinical Strategies for the Blockade of IL-18 in Inflammatory Bowel Diseases
Volume: 14 Issue: 12
Author(s): Takanori Kanai, Nobuhiko Kamada and Tadakazu Hisamatsu
Affiliation:
Keywords: IL-18, IL-18BP, inflammatory bowel disease, Crohn’s disease, ulcerative colitis.
Abstract: Interleukin 18 (IL-18) is an IL-1 super family cytokine that is involved in infection, inflammation and autoimmune diseases. Mounting evidence suggests that IL-18 exert a dual role in inflammation and homeostasis. IL-18 can act as a promoter of T cell immunities, such as type 1 and 17 helper T cell responses, and thus enhances T cell-mediated inflammation, whereas IL-18 increases the barrier function and regeneration of epithelial cells and protects the host from inflammatory stimuli. Although the functional role of IL-18 in regulation of inflammation remains controversial, accumulating evidence indicates the contribution of IL-18 to the pathogenesis of inflammatory bowel diseases (IBD). For example, levels of serum and/or mucosal IL-18 and IL-18 binding protein are elevated in the patients with IBD. Furthermore, polymorphisms in IL-18 and IL-18-related molecules, such as the IL-18 receptor and/or an IL-18 activator NLRP3, genes are found in the patients with IBD. Thus, these preclinical data imply that IL-18 can be a novel therapeutic target for the treatment of IBD. In this review, we focus on IL-18 biology and physiological roles in animal models and human IBD, to provide an outline for development of IL-18 blockade strategies.
Export Options
About this article
Cite this article as:
Kanai Takanori, Kamada Nobuhiko and Hisamatsu Tadakazu, Clinical Strategies for the Blockade of IL-18 in Inflammatory Bowel Diseases, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113149990006
DOI https://dx.doi.org/10.2174/13894501113149990006 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Current Status and Progress of Radiopharmaceuticals for Molecular Imaging and Targeted Therapy)
Current Medicinal Chemistry One Pot Synthesis, Characterization, DFT Studies and AIM Analyses of Ethyl-1-aryl-1H-tetrazole-5-carboxylate
Letters in Organic Chemistry Discovery of New Inhibitors of Urease Enzyme: A Study Using STD-NMR Spectroscopy
Letters in Drug Design & Discovery Cefixime-induced Oromandibular Dystonia in an Adult: A Case Report
Current Drug Safety The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of <i>in vitro</i> and <i>in vivo</i> Models
Current Pharmaceutical Design Understanding the Potential Role and Delivery Approaches of Nitric Oxide in Chronic Wound Healing Management
Current Pharmaceutical Design Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment
Current Medicinal Chemistry Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
CNS & Neurological Disorders - Drug Targets Microtubules (tau) as an Emerging Therapeutic Target: NAP (Davunetide)
Current Pharmaceutical Design Peptide Therapeutics in Neurodegenerative Disorders
Current Medicinal Chemistry Editorial [Hot Topic: Ion Channels: Applications in Ion Channel Drug Discovery(Guest Editor: Douglas S. Krafte)]
Combinatorial Chemistry & High Throughput Screening Pyridoxal 5-Phosphate Enzymes as Targets for Therapeutic Agents
Current Medicinal Chemistry Consensus Guideline Based Therapeutic Drug Monitoring (TDM) in Psychiatry and Neurology
Current Drug Delivery Antiobesity Carbonic Anhydrase Inhibitors
Current Topics in Medicinal Chemistry Benzimidazole Derivatives as Centerally Acting Agents
Current Drug Therapy Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
CNS & Neurological Disorders - Drug Targets Amygdalar Atrophy in Early Alzheimer’s Disease
Current Alzheimer Research Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry